What is the false‑positive rate of the 4Kscore test for detecting clinically significant prostate cancer in men aged 45 years and older with elevated PSA and no prior prostate cancer diagnosis?

False Positive Rate of 4Kscore Test for Prostate Cancer

The 4Kscore test does not have a traditionally defined "false positive rate" because it reports a continuous probability (percent likelihood) of high-grade cancer rather than a binary positive/negative result—however, the test's specificity characteristics show that at commonly used thresholds, approximately 58-72% of men with elevated 4Kscore values will NOT have high-grade prostate cancer on biopsy 1.

Understanding 4Kscore Performance Characteristics

The 4Kscore differs fundamentally from traditional screening tests because it provides a percentage risk estimate rather than a positive/negative cutoff 1. This means the "false positive rate" depends entirely on which threshold you choose to trigger biopsy.

Key Performance Data from Validation Studies

At a 15% risk threshold 1:

• Positive Predictive Value (PPV): Only ~18% of men above this threshold actually had high-grade cancer
• This means approximately 82% would be "false positives" (no high-grade cancer found)
• However, this threshold allowed 58% of biopsies to be avoided while missing only 4.7% of high-grade tumors

At a 6% risk threshold 1:

• 119 of 133 high-grade cancers were detected (89.5% sensitivity)
• 14 of 133 high-grade cancers were missed (10.5% false negative rate)
• 428 of 1000 men could avoid biopsy

Discrimination Performance:

• Area under the curve (AUC) of 0.82 in multiple prospective studies 1, 2
• This indicates good but not perfect discrimination between men with and without high-grade cancer

Critical Context: No Established Cutoff Threshold

A major limitation is that no standardized cutoff threshold has been established for the 4Kscore 1. The NCCN guidelines explicitly state that patients and urologists must discuss results individually to decide whether to proceed with biopsy. This lack of standardization means:

• Different clinicians may use different thresholds
• The "false positive rate" varies dramatically based on chosen cutoff
• Lower thresholds = more false positives but fewer missed cancers
• Higher thresholds = fewer false positives but more missed cancers

Recent Evidence Adds Important Nuance

The most recent high-quality study from 2024 2 in the GÖTEBORG-2 screening trial showed:

• At 7.5% cutoff: PPV of only 15% (meaning 85% false positive rate)
• NPV of 99% (excellent at ruling out high-grade cancer)
• Would avoid MRI in 41% of men and biopsies in 28%
• Would delay diagnosis in 4% of men with intermediate-grade cancer

However, a 2025 European study 3 found the 4Kscore did NOT significantly improve prediction over PSA alone for medium- to long-term risk, except potentially in younger men (<60 years) with elevated PSA.

Practical Clinical Implications

When False Positives Matter Most:

• Younger men who want to avoid unnecessary biopsies and their complications
• Men with PSA 3-10 ng/mL where the test performs optimally 1
• Initial biopsy decisions where avoiding overdiagnosis is prioritized

Common Pitfalls to Avoid:

1. Don't use 4Kscore as a binary test—it's a continuous risk estimate requiring shared decision-making
2. Don't assume a "low" score eliminates cancer risk—approximately 10-15% of high-grade cancers may be missed depending on threshold 1
3. Don't use in men with prior negative biopsy alone—NCCN recommends it can be considered but other tests may be more appropriate 1
4. Beware of large prostates—benign prostatic hyperplasia may elevate scores; consider 4K Density adjustment 4

The Bottom Line on "False Positives":

If you define "false positive" as men who undergo biopsy based on elevated 4Kscore but have no high-grade cancer, the rate ranges from 52-85% depending on the threshold used. The test is better at ruling OUT high-grade cancer (high NPV ~99%) than ruling it IN (low PPV 15-48%). This makes it most useful for avoiding unnecessary biopsies in lower-risk men rather than as a definitive indicator that biopsy is needed.